搜索-Anhui Lianchuang Biological Medicine Co.,Ltd

CN

About us

Product

News

Human resource

Contact

Found for you 10 Results that match

China officially joins ICH and truly integrates into the international drug regulatory system

China has long been excluded from ICH membership because its recognized drug policies and regulations largely comply with WHO (World Health Organization) standards. And WHO is considered the global minimum standard, while ICH is the lowest in developed countries
General Administration approves the marketing of dalatavir hydrochloride tablets and aspirin soft capsules

On April 28, 2017, the State Food and Drug Administration approved the import and marketing of Dalatavir Hydrochloride Tablets and Asurivir Soft Capsules for the combined treatment of adult chronic hepatitis C. Chronic hepatitis C (CHC) is a common chronic disease in clinical practice
SGLT-2 inhibitor first approved for treatment of Type 1 diabetes

On March 25, AstraZeneca announced that the European Medicines Agency (EMA) officially approved its SGLT-2 inhibitor Forxiga (Dapagliflozin
Express | For the treatment of inflammatory spinal disease, AbbVie JAK inhibitor reached the main endpoint of two phase 3 clinical trials

On October 7, 2021, AbbVie announced that its oral JAK inhibitor upadacitinib (trade name in English: Rinvoq) has become a
Express | Targeted STAT3 treatment for hepatocellular carcinoma, innovative therapy qualified for FDA fast track

Recently, TvardiTherapeutics announced that its oral small molecule STAT3 inhibitor TTI-101 has obtained fast channel qualification from the US FDA for the treatment of recurrent/refractory locally advanced, unresectable, or metastatic diseases
Express | AbbVie JAK inhibitor has positive results in the treatment of lupus erythematosus, and has entered the phase 3 clinical trial

AbbVie today announced that its JAK inhibitor upadacitinib (English trade name Rinvoq), in a phase 2 clinical trial, is used as a single drug or combination therapy to treat red spot wolves
June 19-21, 2023, Lianchuang Biomedical has an on-site meeting with you at Shanghai CPHI China 2023

June 19-21, 2023, Lianchuang Biomedical has an on-site meeting with you at Shanghai CPHI China 2023 (Booth: E4 A80)
The 2021 Shareholders' Meeting and Strategic Investment Signing Ceremony of Lianchuang Biomedical was Successfully Held

On December 17th, the "2021 Shareholders' Meeting and Strategic Investment Signing Ceremony" of Anhui Lianchuang Biopharmaceutical Co., Ltd. was successfully held at the Hongrui Jinling Hotel in Hefei, with General Manager Wu Qihua presiding over the meeting. Shareholders' representatives attend the meeting.
Yida Capital has completed a round A investment of nearly 100 million yuan in Lianchuang Biotechnology

Around November 2021, Yida Capital completed a round A investment of nearly 100 million yuan in Anhui Lianchuang Biomedical Co., Ltd. (referred to as Lianchuang Biotechnology). The financing funds will be used for the development of new varieties, the construction of new production bases, and the construction of contract research and development production platforms
Unite Together to Fight the Epidemic - The Party Branch of Anhui Lianchuang Biopharmaceutical Co., Ltd. Donates Materials to Feixi Economic and Technological Development Zone

On May 6, 2022, the branch committee of Anhui Lianchuang Biomedical Co., Ltd. donated materials to the first-line anti epidemic units in Feixi Economic Development Zone, and expressed respect and condolences to those who have been fighting in the front line of COVID-19 prevention and control.